Literature DB >> 10343181

Incidence and risk factors of benign creatine phosphokinase elevations in chronic psychiatric patients.

T Terao1, S Matsuda, H Kojima, K Okuno, H Hori, A Kaku, N Ueda, A Etoh.   

Abstract

There have been few studies focusing on the creatine phosphokinase (CPK) elevations in chronic psychiatric patients. The survey was conducted prospectively to investigate the incidence and risk factors of CPK elevations in chronic psychiatric patients during a 2-year follow-up period. Sixteen of 32 (50%) patients had maximums of more than 230 U/l (upper limit of our normal range) and 7 (22%) patients had maximums of more than 500 U/l. Surprisingly, 4 (13%) patients had maximums of more than 1,000 U/l after exercises such as swimming and walking. Nonetheless, none of the 16 patients with the CPK elevations developed severe conditions such as rhabdomyolysis despite an absence of therapeutic intervention, and their CPK elevations were proven to be benign. According to the path analysis, usual physical activity and neuroleptic doses seemed to underlie CPK elevations directly. The present findings suggest that not a few chronic psychiatric inpatients may have at least one CPK elevation per 2 years. Patients engaging in more physical activity or receiving higher neuroleptic doses are at greater risk of developing such CPK elevations. However, most of these increases are benign, and it is not considered necessary to treat them.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10343181     DOI: 10.1159/000026580

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  2 in total

Review 1.  Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice.

Authors:  Zacharias G Laoutidis; Kanellos T Kioulos
Journal:  Psychopharmacology (Berl)       Date:  2014-10-16       Impact factor: 4.530

2.  Rhabdomyolysis associated with mania in late life.

Authors:  Nabil Kotbi; Nahla Mahgoub; Josephine Mokonogho; Robert Young
Journal:  Int J Geriatr Psychiatry       Date:  2009-12       Impact factor: 3.485

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.